TOVX
Theriva Biologics Inc.
NYSE MKT: TOVX · HEALTHCARE · BIOTECHNOLOGY
$0.25
+2.02% today
Updated 2026-09-11
Market cap
$11.61M
P/E ratio
0.18
P/S ratio
38.70x
EPS (TTM)
$1.44
Dividend yield
—
52W range
$0 – $1
Volume
1.3M
Theriva Biologics Inc. (TOVX) Financial Forecast & Price Target 2030
Revenue-driven projection model with historical context.
Price target summary
Current price
$0.25
12-Month target
$0.19
2030 Target
—
Intrinsic (DCF)
$0.18
Financial forecast
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $0.0B | $0.0B | $0.0B | $0.0B | $0.0B |
| EPS | — | — | — | — | — |
CAGR applied: — (capped 20%) · P/E: 0.18x (capped 25x) · Margin: 0.00%
Methodology
CAGR-based projection model. Research-backed estimates are being generated — check back soon for analyst consensus and management guidance.